IP Library Granted Patent US 8,404,237
Granted Patent B2
US 8,404,237 · App. 13/472,301 · Granted Mar 26, 2013

Antibodies to the NOTCH1 receptor

Inventors: John A. Lewicki (Los Gatos, CA); Austin Gurney (San Francisco, CA); Timothy Hoey (Hillsborough, CA); Wan-ching Yen (Foster City, CA); Sanjeev Satyal (San Carlos, CA)
Assignee: OncoMed Pharamaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,404,237
App. No.
13/472,301
Granted
Mar 26, 2013
Kind
B2
Abstract

The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.

Claims (19)

1. An isolated monoclonal antibody that specifically binds to a non-ligand binding region of the extracellular domain of human Notch1, wherein the non-ligand binding region comprises epidermal growth factor (EGF) repeats 1-10 or EGF repeats 13-36.

2. The antibody of claim 1 , wherein the non-ligand binding region comprises EGF repeats 1-10.

3. The antibody of claim 2 , wherein the non-ligand binding region comprises EGF repeat 4.

4. The antibody of claim 3 , wherein the antibody is 13M57.

5. The antibody of claim 4 , which is humanized.

6. The antibody of claim 3 , which inhibits growth of tumor cells.

7. A pharmaceutical composition comprising the antibody of claim 3 .

8. The antibody of claim 1 , wherein the non-ligand binding region comprises EGF repeats 13-36.

9. The antibody of claim 8 , wherein the non-ligand binding region comprises EGF repeat 13.

10. The antibody of claim 1 , which is a chimeric antibody.

11. The antibody of claim 1 , which is a humanized antibody.

12. The antibody of claim 1 , which is a human antibody.

13. The antibody of claim 1 , which is an antagonist of human Notch1.

14. A hybridoma producing the antibody of claim 1 .

15. An isolated monoclonal antibody that competes with antibody 13M57 for specific binding to a non-ligand binding region of the extracellular domain of human Notch1.

16. A monoclonal antibody that specifically binds to the extracellular domain of human Notch1, wherein the antibody binds to epidermal growth factor (EGF) repeat 4.

17. The antibody of claim 16 , which is an antagonist of human Notch1.

18. The antibody of claim 16 , which inhibits growth of tumor cells.

19. A pharmaceutical composition comprising the antibody of claim 16 .

Assignments (2)
CHANGE OF NAME Recorded Oct 23, 2020
From: ONCOMED PHARMACEUTICALS, INC.
To: MEREO BIOPHARMA 5, INC.
Reel/Frame 054193/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2012
From: LEWICKI, JOHN A.; GURNEY, AUSTIN L.; HOEY, TIMOTHY C.; YEN, WAN-CHING; SATYAL, SANJEEV H.
To: ONCOMED PHARMACEUTICALS, INC.
Reel/Frame 029130/0123 →
Continuity (6)
Division 13010486 · Jan 20, 2011
Division 11806472 · May 31, 2007
Provisional Application 60812955 · Jun 13, 2006
Provisional Application 60879336 · Jan 9, 2007
Provisional Application 60878661 · Jan 5, 2007
Related Publication 20130030155A1 · Jan 31, 2013